Vectomat Insights has published a comprehensive market research study projecting the global RNA therapeutics market to grow from USD 11,864.3 million in 2025 to USD 38,424.6 million by 2035, expanding at a 12.47% compound annual growth rate (CAGR).Key market highlights include:
- Modalities & Applications: mRNA holds the largest revenue share at 45.9% in 2025 (USD 5,440.4 million), while self-amplifying RNA represents the fastest-growing modality at an 18.6% CAGR, alongside rapid expansion in gene-silencing siRNA therapies (30.0% share). Infectious disease vaccines lead applications at 37.9%, whereas cardiometabolic disease grows fastest at 16.96% annually, and CROs/CDMOs represent the fastest-growing end-user segment at an 18.99% CAGR.
- Regional Performance: North America leads global demand with a 39.0% market share (USD 4,627.1 million), anchored by the United States (USD 3,701.7 million) and five FDA approvals for RNA medicines in 2025. Europe follows at 27.0%, while Asia-Pacific (23.0%) emerges as the fastest-growing geographic region through 2035, led by South Korea's 14.7% CAGR.
- Industry Consolidation & Milestones: Major developments reshaping the competitive landscape include Novartis's USD 12 billion acquisition of Avidity Biosciences, BioNTech's completed acquisition of CureVac, Alnylam Pharmaceuticals' FDA approval for Amvuttra in ATTR cardiomyopathy, and positive Phase 3 melanoma results from Merck and Moderna's personalized mRNA cancer vaccine.
Request a Free Sample
To preview key data tables, segmentation depth, and regional forecasts from the 300-page report covering 35 countries and 15 company profiles, request a free sample at: https://www.vectomatinsights.com/request-sample?report=rna-therapeutics-market
Buy the Full Report
To view licensing options and purchase the complete study, visit: https://www.vectomatinsights.com/checkout?report=rna-therapeutics-market
About Vectomat Insights
Vectomat Insights is an independent market research firm providing analyst-validated intelligence across healthcare and life sciences. Sized bottom-up and validated top-down through an audited 16-step process, our reports deliver 10-year forecasts, country-level breakdowns, and competitive insights for strategic decision-makers.